Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDOV-Immune in Advanced Solid Tumors
NCT07656090Phase 1Enrolling by invitation
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2025
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IDOV-Immune in solid tumor, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Dose Limiting Toxicities at 21 days, Incidence of Adverse Events and Serious Adverse Events at 85 days and 1 more. Started Dec 2025; status: enrolling by invitation.
02
Drugs
IDOV-Immune
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07656090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07656090.